B Cells and Antibody Responses in Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 26 April 2024 | Viewed by 97

Special Issue Editors

Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, London SE1 9RT, UK
Interests: B cell responses in cancer; antibody engineering and glycoengineering; IgE class of antibodies in cancer; antibody Fc-mediated functions in cancer; cancer immunology; cancer immunotherapy; antibody-drug conjugates; melanoma; ovarian cancer; breast cancer; allergo-oncology; ADCC; ADCP; macrophages; monocytes; NK cells
Special Issues, Collections and Topics in MDPI journals
Dr. Joseph G Crompton
E-Mail Website
Guest Editor
Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA
Interests: tertiary lymphoid structures
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

B cells and antibodies are known to contribute diverse protective as well as immunoregulatory functions to human immunity. The role of B cells and antibody responses in orchestrating immune surveillance and immune regulation in cancer has received renewed attention in recent years. While the role of T cells in cancer immunology has been studied extensively, a complete understanding of B cell populations and their effector mechanisms mediating humoral immunity against cancer has yet to be fully elucidated.

Although many causal mechanisms of humoral antitumor immunity have not yet been described, strong positive correlations between B cells and cancer-specific survival and response to therapy have recently been reported. Several studies have demonstrated that the presence of intratumoral B cells and class-switched antibodies may be strongly associated with differential clinical outcomes in several histologies, including sarcoma, melanoma, lung, breast, and colorectal cancers.

This Special Issue will highlight several topics related to B cell immunity, antibody immune surveillance in health and malignant diseases and the influence of therapeutic agents on the humoral responses.

Topics in the Special Issue will include:

  • The dual roles of B cells and antibodies in promoting and inhibiting cancer; 
  • Regulatory functions of B cells;
  • Antitumor functions such as antibody-dependent cell cytotoxicity and phagocytosis;
  • Mechanisms of antigen presentation by B cells;
  • Antibodies as biomarkers of disease risk, detection, and immune monitoring;
  • The importance of cancer-associated tertiary lymphoid structures (TLS);
  • The impact of immunoglobulin repertoire and isotypes on cancer immunosurveillance and treatment response;
  • The crosstalk between oncology treatments, such as antibody and checkpoint inhibitor immunotherapies, and humoral response;
  • Mechanisms of B cell malignancies (leukemia/lymphoma);
  • Recent advances in developing B cell-based immunotherapies and vaccines for the treatment of advanced cancers.

A better understanding of B cell and antibody immune surveillance and their interactions with therapeutic agents harbors significant potential to broaden treatment options and therapy responses for patients with advanced forms of cancer.

Prof. Dr. Sophia Karagiannis
Dr. Joseph G Crompton
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Back to TopTop